Details

Autor(en) / Beteiligte

• Bayatipoor, Hashem
• Mehdizadeh, Saber
• Jafarpour, Roghayeh
• Shojaei, Zeinab
• Pashangzadeh, Salar
• Motallebnezhad, Morteza

Titel

Role of NKT cells in cancer immunotherapy—from bench to bed

Ist Teil von

• Medical oncology (Northwood, London, England), 2022-12, Vol.40 (1), p.29-29, Article 29

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Natural killer T (NKT) cells are a specific T cell subset known to express the αβ-T cell receptor (TCR) for antigens identification and express typical NK cell specifications, such as surface expression of CD56 and CD16 markers as well as production of granzyme. Human NKT cells are divided into two subgroups based on their cytokine receptor and TCR repertoire. Both of them are CD1-restricted and recognize lipid antigens presented by CD1d molecules. Studies have demonstrated that these cells are essential in defense against malignancies. These cells secret proinflammatory and regulatory cytokines that stimulate or suppress immune system responses. In several murine tumor models, activation of type I NKT cells induces tumor rejection and inhibits metastasis’s spread. However, type II NKT cells are associated with an inhibitory and regulatory function during tumor immune responses. Variant NKT cells may suppress tumor immunity via different mechanisms that require cross-talk with other immune-regulatory cells. NKT-like cells display high tumor-killing abilities against many tumor cells. In the recent decade, different studies have been performed based on the application of NKT-based immunotherapy for cancer therapy. Moreover, manipulation of NKT cells through administering autologous dendritic cell (DC) loaded with α-galactosylceramide (α-GalCer) and direct α-GalCer injection has also been tested. In this review, we described different subtypes of NKT cells, their function in the anti-tumor immune responses, and the application of NKT cells in cancer immunotherapy from bench to bed.